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a b s t r a c t
Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph) arising from the
reciprocal t(9;22), but 5–10% present variants of this translocation involving different breakpoints
besides 9q34 and 22q11.
We report the non simultaneous occurrence of two different types of Ph translocation in a CML
patient: a t(9;22)(q34;q11) standard and a three-way variant t(9;11;22)(q34;p15;q11).
Bone marrow cells with standard translocation did not have BCR/ABL kinase domain (KD) mutations
and were sensitive to imatinib therapy. In contrast, bone marrow cells with the variant translocation
showed two BCR/ABL KD mutations and were resistant to imatinib, thus inducing transformation to the
blast phase and karyotype evolution.
& 2013 The Authors. Published by Elsevier Ltd.
1. Case report
A 56-year-old male was admitted to our Hospital in October 2010
because of asthenia, slight fever, and weight loss. Blood examination
revealed hemoglobin 7.5 g/dL, platelet count 495,000/uL, white blood
cell count 335,000/uL with neutrophils 80%, basophils 10%, myelocytes
6%, and promyelocytes 3%. Lactate dehydrogenase was 1440 U/L.
Physical examination revealed splenomegaly. Bone marrow (BM)
aspirate showed myeloid hyperplasia. The hematological picture was
indicative of accelerated phase chronic myeloid leukemia (CML).
Cytogenetic analysis showed the presence of a t(9;22)(q34;q11)
in all examined metaphases (Fig. 1 upper). Fluorescent in situ
hybridization (FISH) using the LSI BCR/ABL Dual-Color, Dual Fusion
(D-FISH) (Abbott Molecular-Vysis, Des Plaines,IL) showed two
fusions, one green and one orange signal (2F1G1O) conﬁrming
the presence of the BCR/ABL1 and ABL1/BCR fusion genes without
deletions adjacent to the translocation junctions (Fig. 2A).
Real-time quantitative polymerase chain reaction (RQ-PCR)
was performed to quantify BCR/ABL1 transcript as described
previously [1]. The quantitative results were expressed as percent
ratios relative to an ABL1 internal control using the following
formula (p210 BCR–ABL/ABL1100CF) [2]. The level of BCR/ABL1
expression was 31% at diagnosis (IS).
The patient was ﬁrst treated with hydroxyurea at 3 g/day for
7 days, after which imatinib (Gleevec, Novartis, Basel, Switzerland)
was administered at a dosage of 600 mg/day.
In January 2011, cytogenetic analysis revealed an unexpected
t(11;22)(p15;q11) with chromosomes 9 apparently not being
involved (Fig. 1 lower). D-FISH signal pattern proved to be
2F1G1O, with one fusion signal on the der(22), a second fusion
signal on 11p15, and one orange and one green signal on normal
chromosomes 9 and 22, respectively (Fig.2B). The karyotype was
then interpreted as t(9;11;22)(q34;p15;q11) [3]. BCR/ABL1 expres-
sion had increased to 39.5% (IS).
The patient was treated with the ICE chemotherapy protocol
consisting of idarubicin 8 mg/m2/day, cytarabine (ARA-C) 800 mg/m2
and etoposide 150 mg/m2/day.
In March 2011, cytogenetic analysis was performed again and
we observed a high number of metaphases: 49 were normal
whereas 23 showed Ph due to the classical translocation. No cells
carrying the variant translocation were observed.
The patient was treated again with imatinib 800 mg/day with-
out hematological response.
In June 2011, white blood cell count was 28,300/uL with 5% of
blasts. The karyotype was: 49,XY,t(9;11;22)(q34;p15;q11),þ6,þ9,
þder(22)t(9;22). No cells carrying the standard translocation were
observed, indicating that for the second time the imatinib therapy
had suppressed the t(9;22) clone, thus allowing the reappearance
of the t(9;11;22) clone.
In July 2011, the patient underwent allogenic bone marrow
transplantation (BMT) from his HLA compatible sister: the karyotype
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was 46,XX and the patient reached and maintained complete hema-
tological and molecular remission until October 2012.
In November 2012, the patient progressed to myeloid blast
crisis and the karyotype became: 47,XY,t(9;11;22)(q34;p15;q11),
þder(22).
The patient died in December 2012.
2. Results
At diagnosis the patient was in accelerated phase CML with
standard translocation. After three months of therapy with
imatinib, cytogenetic analysis revealed the persistence of Ph in all
examined metaphases but with a variant translocation involving a
third chromosome, t(9;11;22) which had not been observed in the
previous cytogenetic analysis (Fig.1).
ICE-chemotherapy, which proved to be clinically unsatisfactory,
apparently reduced the variant translocation clone but led to the
expansion of the Phþ clone with standard translocation.
The following cycle of imatinib 800 mg/day before BMT was
also ineffective. The variant translocation reappeared with addi-
tional chromosomal abnormalities including Ph duplication.
This clone with variant Ph translocation appeared to have been
eradicated by BMT (the patient reached complete molecular
response with RQ-PCR), however, it reappeared 16 months later
causing relapse into the myeloid blastic phase.
Quinacrine-bandend (Q-banded) and FISH techniques revealed
the presence of the two Ph translocations (standard and variant)
alternatively with ABL1/BCR construct location on 9q34 or 11p15
and without adjacent deletions in the junctions of the BCR and/or
ABL1 genes (Fig. 2).
We had never previously observed the simultaneous presence
of cells with the standard translocation and others with the
variant in the same patient.
Considering the alternation of the type of translocation, which
would appear to be related to the kind of therapy, we observed
that cells carrying the standard translocation were sensitive to
imatinib, while the cells bearing the variant translocation were
sensitive to ICE chemotherapy. The BM samples that we had stored
at diagnosis and after three months of imatinib therapy were
therefore screened for kinase domain (KD) mutations in the
BCR–ABL1 gene using direct sequencing as described previously [4].
The BM sample taken at diagnosis showing the standard translocation
had no detectable BCR–ABL1 KDmutation (Table 1, Fig. 3A), while two
different KD mutations were identiﬁed in the sample carrying the
variant translocation: the ﬁrst mutation has already been reported and
was at codon position 255 (E255V), while the second mutation, which
has never previously been described, was at position 258 (E258V)
(Table 1, Fig. 3B–D) [5]. The two mutations led to an A to T transition
that resulted in a glutamic acid to valine substitution in the ABL1
protein and both mutations should be present at higher than 20%.
These point-mutations in the tyrosine kinase domain of
BCR–ABL1 may cause progressive clinical resistance to imatinib
Fig. 1. Q-banded karyotype. Upper: partial Q-banded karyotype showing the
chromosomes 9 and 22 involved in the t(9;22)(q34;q11) as compared with the
chromosomes 11 that were not involved. Lower: partial Q-banded karyotype
showing the chromosomes 11 and 22 involved in the t(11;22)(p15;q11) as
compared with chromosomes 9 that were apparently not involved.
Fig. 2. Fluorescent in situ hybridization. (A) FISH on partial metaphase with t(9;22)(q34;q11) using BCR/ABL Dual Color Dual Fusion translocation, Vysis(D-FISH) and Human
Chromosome 9 Centromeric Cambio probe (20 metaphases and 200 cells analyzed). D-FISH probe: fusion signal (yellow) was present on Philadelphia chromosome and on
the long arm of derivative chromosome 9, one orange signal (ABL probe) was present on the long arm of normal chromosome 9, and one green signal (BCR probe) was
present on the long arm of normal chromosome 22. Human Chromosome 9 Centromeric Cambio probe: two red signals were present on normal and derivative chromosome 9.
(B) FISH on partial metaphase with t(11;22)(p15;q11) using BCR/ABL Dual Color Dual Fusion translocation, Vysis (D-FISH) and Human Chromosome 11 Centromeric Cambio
probe (20 metaphases and 200 cells analyzed). D-FISH probe: fusion signal (yellow) was present on der(22) and on the short arm of derivative chromosome 11, one orange
signal (ABL probe) was present on the long arm of normal chromosome 9, and one green signal (BCR probe) was present on the long arm of normal chromosome 22. Human
Chromosome 11 Centromeric Cambio probe: two red signals were present on normal and derivative chromosome 11. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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and are associated with a greater likelihood of progression to blast
crisis and shorter survival [6].
3. Discussion
Our case presents two points of interest:
1) The presence of both standard and variant Ph translocations in
a single patient. It is likely that the variant translocation
occurred after the formation of the standard one: ABL1/BCR
complex moved from 9q34 band to 11p15 band thereby
restoring apparent cytogenetic integrity to the involved chro-
mosome 9. FISH analysis revealed a 2F1G1O signal pattern
which is indicative of the two-step mechanism of variant
formation [7] without deletions adjacent to the junctions [8].
It is also likely that the variant translocation was already
present at diagnosis but in such a low proportion that it could
not be detected by banding and FISH techniques.
2) The second observation of interest is the fact that the leukemic
cells with standard translocation did not show mutations in
BCR/ABL1 KD and that these cells were sensitive to imatinib. On
the contrary, the cells with the variant translocation had two
KD mutations in the BCR/ABL1 gene i.e., E255V, which is known
to confer resistance to imatinib, and E258V, whose biological
signiﬁcance and ability to confer resistance is unknown [5].
The presence of the two KD mutations in cells with the variant
translocation alone is not easy to interpret. It seems unlikely that
the transposition of the complex ABL1/BCR from 9q34 to 11p15 is
correlated with the occurrence of mutations.
Of the mechanisms of resistance to imatinib, point mutations in
the ABL1 KD are among the most frequently investigated. Several
mutations are known to confer differing levels of resistance to the
available tyrosine kinase inhibitors [5].
The modalities of occurrence and/or selection of mutations in
the ABL1 KD sequence are under investigation, but some authors
believe that the mutations can antedate treatment with imatinib
[9]. This theory is in agreement with the hypothesis that the KD
mutations in our patient were present in a number of proliferating
leukemic cells, and that imatinib rapidly selected the clone bearing
the mutations. Establishing the presence of leukemic clones with
KD mutations as early on as possible could therefore lead to the
timely use of different tyrosine kinase inhibitors [10].
In conclusion, we demonstrated that cells with the standard
Ph had no detectable BCR–ABL1 KD mutations and that they
were responsive to imatinib therapy, while cells with the variant
Table 1
Karyotypes and Kinase domain (KD) mutations during the course of the disease. Correlation between karyotypes and KD mutations in order to monitor the cytogenetic and
molecular changes.
Months Karyotypes BCR–ABL1 Kinase Domain mutation
At diagnosis (October 2010) 46,XY,t(9;22)(q34;q11), [20 metaphases] native BCR–ABL1
3 months (January 2011) 46,XY,t(9;11;22)(q34;p15;q11), [20 metaphases] low- level mutation: E255V and E258V
5 months (March 2011) 46,XY [49 metaphases]/46,XY,t(9;22)(q34;q11), [23 metaphases] native BCR–ABL1
8 months (June 2011) 49,XY,t(9;11;22)(q34;p15;q11),þ6,þ9,þder(22) t(9;22),
[20 metaphases]
low- level mutation: E255V and E258V
9 months- 24 months (July 2011–October 2012)
after BMT
46,XX, [20 metaphases] BCR–ABL1 not present
25 months (November 2012) 47,XY,t(9;11;22)(q34;p15;q11),þder(22). [20 metaphases] increase of level mutation E255V and E258V
Fig. 3. Kinase domain (KD) mutations. Evidence of a BCR/ABL1 kinase domain mutation by direct sequencing (ABL sequence accession number X16416): at diagnosis native
BCR–ABL1 (A); detection at 3–8 months of low- level mutation of residues 255EoV and 258 EoV, common nucleotide changes A4T (B, C) and increase of level mutation at
25 months after BMT in myeloid blastic phase. (D).
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translocation harbored two KD mutations, a previously described
one and a never previously reported one [5]. These cells were
resistant to imatinib, and in our case they were associated with the
transformation to blast phase with karyotype evolution.
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